Yüklüyor......
Preliminary evaluation of prostate‐targeted radiotherapy using (131)I‐MIP‐1095 in combination with radiosensitising chemotherapeutic drugs
OBJECTIVES: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy. (131)I‐MIP‐1095 is a recently developed prostate‐specific membrane antigen (PSMA)‐targeting, small molecular weight radio...
Kaydedildi:
| Yayımlandı: | J Pharm Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5298040/ https://ncbi.nlm.nih.gov/pubmed/27139157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jphp.12558 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|